ESLR group (n = 291) | Conventional group (n = 102) | P | |
---|---|---|---|
Age (years) | 60.79 ± 7.96 | 59.72 ± 8.80 | 0.253 |
Gender (n) | 0.211 | ||
male | 241(82.82%) | 90(88.24%) | |
female | 50(17.18%) | 12(11.76%) | |
Comorbidity (n) | |||
Hypertension | 105(36.08%) | 34(33.33%) | 0.633 |
Diabetes | 41(14.09%) | 12(11.76%) | 0.617 |
COPD | 32(11.00%) | 15(14.71%) | 0.375 |
Others | 21(7.22%) | 9(8.82%) | 0.665 |
Tumour locationa (n) | 0.728 | ||
Upper thoracic | 21(7.22%) | 5(4.91%) | |
Middle thoracic | 162(55.67%) | 59(57.84%) | |
Lower thoracic | 108(37.11%) | 38(37.25%) | |
Clinical stages (n) | 0.888 | ||
I | 43(14.78%) | 13(12.75%) | |
II | 187(64.26%) | 67(65.69%) | |
III | 61(20.96%) | 22(21.56%) | |
Neoadjuvant treatment (n) | 97(33.33%) | 30(29.41%) | 0.274 |
Surgeons (n) | 0.222 | ||
Doctor 1 | 105(36.08%) | 30(29.41%) | |
Doctor 2 | 186(63.92%) | 72(70.59%) |